Sign in

    Luis Santos

    Senior Equity Research Associate at H.C. Wainwright & Co.

    Luis Santos, PhD, is a Senior Equity Research Associate at H.C. Wainwright & Co., specializing in healthcare and biotechnology with a particular focus on emerging gene therapy, gene editing, and RNA therapeutics companies. He covers firms such as Sangamo Therapeutics and Freeline Therapeutics, leveraging a robust scientific background and extensive postdoctoral experience in oncology, metabolism, and drug resistance. Before joining H.C. Wainwright, Santos held a similar research role at Chardan, and also contributed to biotech innovation as a co-founder, guest lecturer, and program manager at Columbia University Medical Center. Santos holds a PhD in biological sciences from Columbia University and combines deep technical expertise with equity research, although FINRA registration or securities-license detail is not indicated by public records.

    Luis Santos's questions to SANGAMO THERAPEUTICS (SGMO) leadership

    Luis Santos's questions to SANGAMO THERAPEUTICS (SGMO) leadership • Q2 2025

    Question

    Luis Santos of H.C. Wainwright & Co., LLC inquired about the company's cash runway and the impact of the STAND trial initiation on cash burn. He also asked for updates on the MINT platform and what kind of data to expect from the STAND trial by the end of the next year.

    Answer

    CFO Prathyusha Duraibabu stated that the top priority is securing a Fabry commercialization partner to solve funding needs, but the intent is to continue advancing the pain program as planned. Head of Research & Technology Gregory Davis mentioned ongoing partnership discussions for the MINT platform. Regarding the STAND trial, CEO Sandy Macrae and CDO Nathalie Dubois-Stringfellow confirmed that initial safety and early efficacy data from the dose escalation, with a 12-week endpoint, would be expected by the end of 2026.

    Ask Fintool Equity Research AI

    Luis Santos's questions to SANGAMO THERAPEUTICS (SGMO) leadership • Q1 2025

    Question

    Luis Santos of H.C. Wainwright & Co. asked for an update on the Fabry program, questioning if patients previously on enzyme replacement therapy (ERT) remain off it. He also requested more detail on the eGFR slope's statistical significance and which patient data would be included in the final BLA analysis.

    Answer

    Chief Development Officer Nathalie Dubois-Stringfellow confirmed that all 18 patients who were on ERT are still off the therapy. While not commenting on specific statistical thresholds, she and CEO Alexander Macrae reiterated that the mean eGFR slope remains positive, a clinically meaningful result. CFO Prathyusha Duraibabu and Macrae clarified that the BLA submission will include data from all 32 patients at one year and 19 patients at two years.

    Ask Fintool Equity Research AI

    Luis Santos's questions to Mind Medicine (MindMed) (MNMD) leadership

    Luis Santos's questions to Mind Medicine (MindMed) (MNMD) leadership • Q2 2025

    Question

    Luis Santos from H.C. Wainwright & Co., LLC, on behalf of Patrick Trujillo, requested an update on collaborations with treatment centers regarding patient monitoring time and the potential reimbursement landscape, including Medicare.

    Answer

    CEO & Board Director Robert Barrow explained that the Phase 3 program is designed to collect structured data on the dynamics of a single administration, including time in the clinic, which will be analyzed. He added that while the company has strong engagement with payers, it is premature to discuss specific reimbursement details or dollar amounts.

    Ask Fintool Equity Research AI

    Luis Santos's questions to Mind Medicine (MindMed) (MNMD) leadership • Q2 2025

    Question

    Speaking for Patrick Trujillo, Luis Santos from H.C. Wainwright & Co., LLC asked for an update on collaborations with treatment centers regarding in-clinic monitoring time and on the reimbursement strategy, particularly its fit with Medicare.

    Answer

    CEO Robert Barrow explained that the Phase 3 trials are designed to collect structured data on in-clinic time, which will provide clarity in the future. On reimbursement, he stated it was premature to discuss specific figures but confirmed the company has had strong engagement with payers and feels confident in its approach.

    Ask Fintool Equity Research AI

    Luis Santos's questions to COMPASS Pathways (CMPS) leadership

    Luis Santos's questions to COMPASS Pathways (CMPS) leadership • Q2 2025

    Question

    Luis Santos from H.C. Wainwright & Co., LLC asked about the progress of strategic collaborations with interventional psychiatry centers and the feedback received regarding their readiness to deliver COMP360 if approved.

    Answer

    Chief Patient Officer Steve Levine stated that ongoing collaborations with a broad range of mental health providers, including existing SPRAVATO centers, confirm that COMP360 can fit directly into the current infrastructure. He expressed high confidence that the existing network, including room setups and staffing, is ready for COMP360 delivery upon a potential approval.

    Ask Fintool Equity Research AI

    Luis Santos's questions to ONCOLYTICS BIOTECH (ONCY) leadership

    Luis Santos's questions to ONCOLYTICS BIOTECH (ONCY) leadership • Q4 2024

    Question

    Luis Santos of H.C. Wainwright & Co., on behalf of Patrick Trucchio, asked about the commercial positioning of pelareorep in breast cancer given the rise of antibody-drug conjugates (ADCs), and questioned the potential for combination therapies with ADCs.

    Answer

    Chief Medical Officer Dr. Tom Heineman clarified that the primary target population includes patients who have progressed after ADC therapy, a large and growing group. He also noted that while combination therapy with ADCs is a logical future step, it is not part of the immediate development path. VP of Business Development Christophe DeGois reinforced the market potential, citing an addressable population of 55,000 U.S. patients annually post-ADC treatment, which supports a potential $2.4 billion market.

    Ask Fintool Equity Research AI

    Luis Santos's questions to Harmony Biosciences Holdings (HRMY) leadership

    Luis Santos's questions to Harmony Biosciences Holdings (HRMY) leadership • Q4 2024

    Question

    Luis Santos, on behalf of Patrick Trucchio, asked about the Pitolisant GR formulation, inquiring what data points from the upcoming bioequivalence study would support a regulatory submission and confirming the timeline for a 2026 PDUFA date.

    Answer

    Dr. Kumar Budur, Chief Medical and Scientific Officer, confirmed the pivotal bioequivalence study will start in the current quarter with top-line data expected in Q3. He explained that the study aims to show standard bioequivalence (80%-125% range for Cmax and AUC) and reaffirmed that the program is on track for a 2026 PDUFA date.

    Ask Fintool Equity Research AI